Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.35 is 85% above its 5-year average of -9.12, near the high end of its 5-year range (-17.41–-1.35).
61.92% above its 12-month average of -3.54.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.26.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 22 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.35
EARNINGS PER SHARE (EPS) AVG TTM
-3.54
EARNINGS PER SHARE (EPS) AVG 3Y
-9.29
EARNINGS PER SHARE (EPS) AVG 5Y
-9.12
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+61.92%
CURRENT VS 3Y AVG
+85.47%
CURRENT VS 5Y AVG
+85.20%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Lucyd, Inc
Market Cap
$5.83M
Earnings Per Share (EPS)
-1.35
TTM Avg
-3.54
3Y Avg
-9.29
5Y Avg
-9.12
Market Cap
$5.82M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.92
3Y Avg
-0.62
5Y Avg
-0.53
Market Cap
$5.89M
Earnings Per Share (EPS)
-1.22
TTM Avg
-2.34
3Y Avg
-6.29
5Y Avg
-11.33
Market Cap
$5.92M
Earnings Per Share (EPS)
-2.92
TTM Avg
-6.51
3Y Avg
-19.53
5Y Avg
-13.36
Market Cap
$5.73M
Earnings Per Share (EPS)
537.52
TTM Avg
197.33
3Y Avg
123.75
5Y Avg
69.48
Market Cap
$5.70M
Earnings Per Share (EPS)
-520.08
TTM Avg
-794.41
3Y Avg
-1655.89
5Y Avg
-3031.26
Market Cap
$5.63M
Earnings Per Share (EPS)
-3.55
TTM Avg
-11.46
3Y Avg
-17.07
5Y Avg
-17.09
Market Cap
$6.11M
Earnings Per Share (EPS)
N/A
TTM Avg
-258.25
3Y Avg
-228.81
5Y Avg
-176.13
Market Cap
$6.28M
Earnings Per Share (EPS)
-4.57
TTM Avg
-13.10
3Y Avg
-16.05
5Y Avg
-14.80
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lucyd, Inc (LUCY) | $5.83M | -1.35 | -3.54 | -9.29 | -9.12 |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.82M | N/A | -0.92 | -0.62 | -0.53 |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.89M | -1.22 | -2.34 | -6.29 | -11.33 |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.92M | -2.92 | -6.51 | -19.53 | -13.36 |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.73M | 537.52 | 197.33 | 123.75 | 69.48 |
| enVVeno Medical Corporation (NVNO)vs › | $5.70M | -520.08 | -794.41 | -1655.89 | -3031.26 |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | -3.55 | -11.46 | -17.07 | -17.09 |
| Scienture Holdings, Inc. (SCNX)vs › | $6.11M | N/A | -258.25 | -228.81 | -176.13 |
| Femasys Inc. (FEMY)vs › | $6.28M | -4.57 | -13.10 | -16.05 | -14.80 |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.35M | -5.32 | -8.47 | -12.67 | -14.30 |
Trailing EPS (TTM)
$-1.35
Forward EPS (Est.)
$-1.23
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.90 |
| 2024-12-31 | -5.19 |
| 2023-12-31 | -12.67 |
| 2022-12-31 | -17.41 |
| 2021-12-31 | -12.37 |
| 2020-12-31 | -5.19 |
| 2019-12-31 | -2.64 |
